Mark O’Mahony
Fortuna: 16 253 $ al 31/07/2026
Fortuna: 16 253 $ al 31/07/2026
Mark O’Mahony formerly worked at Millennium Pharmaceuticals, Inc., as Principal in 2000, LeukoSite, Inc., as Principal in 2000, Tolerx, Inc., as VP-Process Development & Manufacturing from 2000 to 2011, DecImmune Therapeutics, Inc., as Vice President-Manufacturing & Quality, Serono Corp., as Principal, and Leap Therapeutics, Inc., as Vice President-Manufacturing from 2011 to 2020.
Mr. O’Mahony received his Masters Business Admin degree from Boston University and undergraduate degree from University College Dublin.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 28/03/2025 | 27.500 ( 0,03 % ) | 16 253 $ | 31/07/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Corporate Officer/Principal | 19/12/2011 |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Corporate Officer/Principal | 01/01/2000 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | 01/01/2000 |
| CYPHERPUNK TECHNOLOGIES INC. | Corporate Officer/Principal | - |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology Develops novel peptides and antibodies for acute and tissue damaging inflammation | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 8 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology Develops novel peptides and antibodies for acute and tissue damaging inflammation | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College Dublin
University College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Serono Corp. | |
Leap Therapeutics, Inc.
Leap Therapeutics, Inc. BiotechnologyHealth Technology Engages in clinical stage immuno-oncology | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.